Close
Enter your
text here

Biosimilars

Insurance-Driven Switches to Adalimumab Biosimilars Maintain Disease Control in Pediatric Inflammatory Bowel Disease
 Insurance-Driven Switches to Adalimumab Biosimilars Maintain Disease Control in Pediatric Inflammatory Bowel Disease 1024 683 Pam Georgiana
By: Pam Georgiana
Woman in scrubs with a stethoscope talking with teen.

New pediatric data may help clinicians reassure patients and families about nonmedical treatment switches Since biosimilar versions of adalimumab became available in the United States in 2023, more insurers have required patients receiving the originator medication to switch to a biosimilar. Researchers have deemed biosimilars safe and effective alternatives in adults. However, there is limited…

Infliximab Biosimilars Improve Growth Outcomes in Children With Inflammatory Bowel Disease
 Infliximab Biosimilars Improve Growth Outcomes in Children With Inflammatory Bowel Disease 1024 683 Mary Bates, PhD
By: Mary Bates, PhD

Treatment with either the infliximab originator or a biosimilar improves clinical and growth outcomes. In a new study, researchers at Nationwide Children’s Hospital report that children with inflammatory bowel disease showed similar growth and clinical outcomes whether they were treated with the infliximab originator or a biosimilar agent. The results add to the growing literature…

How Do Children With IBD and Their Caregivers Perceive Biosimilars?
 How Do Children With IBD and Their Caregivers Perceive Biosimilars? 640 427 JoAnna Pendergrass, DVM
By: JoAnna Pendergrass, DVM

Many pediatric patients with inflammatory bowel disease and their caregivers are unaware of biosimilars, creating an opportunity for providers to educate patients and their families about this effective and less expensive treatment option. Infliximab is a biologic therapy that effectively manages inflammatory bowel disease (IBD) in adult and pediatric patients. However, biologic therapies are expensive,…